CNS, or central nervous system, disorders such as schizophrenia, bipolar depression, epilepsy, and Parkinson’s disease have historically been some of the most difficult to treat. Collective progress has waxed and waned, but, over the last decade, Sunovion Pharmaceutical has been a constant driver of innovation and advancements. This article explores how Sunovion’s findings have brought new hope to patients and their loved ones, as well as the steps the company is taking to prepare for a transformative future.

View the article

Leave a Reply